You are accessing a global website, please note that this product is currently only marketed in the United States of America.
BECAUSE THE TRUTH MATTERS.
What is COLVERA®?
COLVERA is a circulating tumor DNA (ctDNA) liquid biopsy test designed to detect both minimal residual disease and recurrent disease in colorectal cancer (CRC) patients.
How does COLVERA work?
During cancer growth and spreading, tumors can begin to release DNA into the bloodstream. These molecules released are known as ctDNA.
COLVERA is a qualitative blood test designed to detect residual and recurrent colorectal cancer by identifying the presence of two methylated genes, BCAT1 and IKZF1, in ctDNA associated with colorectal tumor growth.
By indicating the presence or absence of these methylated genes, COLVERA may help to provide more information about whether additional follow-up, such as radiological imaging, should be considered.
In a head to head clinical evaluation, COLVERA detected
colorectal cancer recurrences compared to CEA
When to use COLVERA?
COLVERA can be ordered with or without CEA:
- For the detection of residual disease post-surgical resection
- For surveillance of recurrent colorectal cancer after primary treatment.
In a head to head clinical study, COLVERA detected twice the number of recurrent colorectal cancer cases compared to CEA. Of 122 patients who were tested after completion of their initial therapy, 28 patients developed recurrent disease confirmed by CT scan. COLVERA detected recurrence in 19 of the 28 patients compared to only 9 of 28 patients detected by CEA.1
By using COLVERA in combination with CEA, additional information will be provided that may help to more confidently manage patients, and identify residual or recurrent colorectal cancer before symptoms present and cancer has spread to other areas of the body.
COLVERA is not intended for screening at this time.
Copyright © 2018 Clinical Genomics Technologies Pty Ltd. All Rights Reserved.